[go: up one dir, main page]

MX2020010110A - Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. - Google Patents

Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.

Info

Publication number
MX2020010110A
MX2020010110A MX2020010110A MX2020010110A MX2020010110A MX 2020010110 A MX2020010110 A MX 2020010110A MX 2020010110 A MX2020010110 A MX 2020010110A MX 2020010110 A MX2020010110 A MX 2020010110A MX 2020010110 A MX2020010110 A MX 2020010110A
Authority
MX
Mexico
Prior art keywords
binding agents
drug conjugates
monoclonal binding
cmet monoclonal
cmet
Prior art date
Application number
MX2020010110A
Other languages
English (en)
Inventor
Marco Gymnopoulos
Roland Newman
Julia Coronella
Ryo Fujita
Vincent Blot
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2020010110A publication Critical patent/MX2020010110A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Aquí se presentan agentes de unión de cMET monoclonales novedosos que son conjugados a toxinas de pirrolobenzodazepina, una composición de los mismos y usos de los mismos para el tratamiento de cáncer.
MX2020010110A 2018-03-28 2019-03-27 Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. MX2020010110A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862649078P 2018-03-28 2018-03-28
PCT/JP2019/013345 WO2019189453A1 (en) 2018-03-28 2019-03-27 DRUG CONJUGATES OF cMET MONOCLONAL BINDING AGENTS, AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2020010110A true MX2020010110A (es) 2020-11-06

Family

ID=68059106

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010110A MX2020010110A (es) 2018-03-28 2019-03-27 Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.

Country Status (17)

Country Link
US (2) US12060427B2 (es)
EP (1) EP3774923A4 (es)
JP (4) JP7177848B2 (es)
KR (1) KR20200138288A (es)
CN (2) CN120586086A (es)
AU (1) AU2019243764B2 (es)
BR (1) BR112020019465A2 (es)
CA (1) CA3094827A1 (es)
IL (1) IL277573B1 (es)
MA (1) MA52238A (es)
MX (1) MX2020010110A (es)
MY (1) MY208842A (es)
PH (1) PH12020551556A1 (es)
SA (1) SA520420225B1 (es)
SG (1) SG11202009308WA (es)
TW (1) TWI841555B (es)
WO (1) WO2019189453A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020180110A (ja) * 2019-03-29 2020-11-05 田辺三菱製薬株式会社 ｃＭＥＴモノクローナル結合剤の薬物複合体を含む医薬組成物
CN111363042B (zh) * 2020-03-30 2022-02-11 中国人民解放军第四军医大学 一种高特异性抗小鼠cd226单克隆抗体及其应用
DK4288456T3 (da) * 2021-02-03 2024-11-25 Mythic Therapeutics Inc Anti-met-antistoffer og anvendelser deraf
JP2024515266A (ja) * 2021-04-08 2024-04-08 ビョンディス・ビー．ブイ． 抗ｃ－ＭＥＴ抗体及び抗体薬物複合体

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6066718A (en) 1992-09-25 2000-05-23 Novartis Corporation Reshaped monoclonal antibodies against an immunoglobulin isotype
US5686070A (en) 1994-03-03 1997-11-11 Genentech, Inc. Methods for treating bacterial pneumonia
HU221385B1 (en) 1994-07-13 2002-09-28 Chugai Pharmaceutical Co Ltd Reconstituted human antibody against human interleukin-8
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
AU2004284075A1 (en) 2003-10-22 2005-05-06 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
DE602006011300D1 (de) 2005-04-21 2010-02-04 Spirogen Ltd Pyrrolobenzodiazepine
ES2368864T3 (es) 2006-02-06 2011-11-23 Metheresis Translational Research Sa Anticuerpos monoclonales anti-met, sus fragmentos y vectores para el tratamiento de tumores y productos correspondientes.
US7910702B2 (en) * 2006-07-28 2011-03-22 The Governors Of The University Of Alberta Recombinant antibodies to sclerotinia antigens
MX2010009669A (es) * 2008-03-06 2010-09-22 Genentech Inc Terapia de combinacion con antagonistas de c-met y egfr.
MY197840A (en) 2008-04-30 2023-07-20 Immunogen Inc Cross-linkers and their uses
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
GB0819097D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
PT2437790T (pt) 2009-06-03 2019-06-04 Immunogen Inc Métodos de conjugação
AU2011239522B2 (en) 2010-04-15 2014-10-23 Medimmune Limited Targeted pyrrolobenzodiazapine conjugates
WO2011130598A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
JP5875083B2 (ja) 2010-04-15 2016-03-02 メディミューン リミテッド 増殖性疾患治療用ピロロベンゾジアゼピン
GB201006340D0 (en) 2010-04-15 2010-06-02 Spirogen Ltd Synthesis method and intermediates
PL2675479T3 (pl) 2011-02-15 2016-09-30 Cytotoksyczne pochodne benzodiazepiny
BR112013027224A8 (pt) * 2011-04-22 2018-08-14 Emergent Product Dev Seattle Proteínas de ligação de antígeno de membrana específico de próstata e composições e métodos relacionados
SMT201900500T1 (it) 2011-05-08 2019-11-13 Legochem Biosciences Inc Coniugati di agente protettivo-proteina e metodo per preparare i medesimi
AU2012311505B2 (en) 2011-09-20 2016-09-29 Medimmune Limited Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
SG11201401406YA (en) 2011-10-14 2014-05-29 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
CN103987384A (zh) 2011-10-14 2014-08-13 西雅图基因公司 吡咯并苯并二氮杂卓和靶向结合物
CA2850264C (en) 2011-10-14 2019-11-05 Spirogen Sarl Pyrrolobenzodiazepines
AU2012322933B2 (en) 2011-10-14 2017-02-02 Medimmune Limited Synthesis method and intermediates useful in the preparation of pyrrolobenzodiazepines
JP6170497B2 (ja) 2011-10-14 2017-07-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン
EA026643B1 (ru) 2011-10-14 2017-04-28 Сиэтл Дженетикс, Инк. Пирролбензодиазепины и конъюгаты направленного действия
KR101463098B1 (ko) 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
EP2650335B1 (en) 2012-04-13 2018-05-30 Tata Consultancy Services Ltd. A process for synthesis of doped titania nanoparticles having photocatalytic activity in sunlight
EP2855482B1 (en) 2012-04-30 2017-03-01 MedImmune Limited Pyrrolobenzodiazepines
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
CA3060520C (en) 2012-10-12 2022-05-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CA2941485C (en) 2012-10-12 2018-06-12 Philip Wilson Howard Pyrrolobenzodiazepines and conjugates thereof
HRP20171264T1 (hr) 2012-10-12 2017-10-20 Adc Therapeutics Sa Konjugati protutijela anti-her2-pirolobenzodiazepina
US20150368329A1 (en) * 2012-10-15 2015-12-24 Oncomed Pharmaceuticals, Inc. Methods of Treating Ocular Diseases
ES2701076T3 (es) 2012-11-24 2019-02-20 Hangzhou Dac Biotech Co Ltd Enlazadores hidrofílicos y sus usos para la conjugación de fármacos a las moléculas que se unen a las células
EA031585B1 (ru) 2012-12-21 2019-01-31 Медимьюн Лимитед Пирролобензодиазепины и их конъюгаты
WO2014096365A1 (en) 2012-12-21 2014-06-26 Spirogen Sàrl Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
RU2019109456A (ru) 2013-02-22 2019-04-10 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые конъюгаты антител и их применения
US20160031887A1 (en) 2013-03-13 2016-02-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX364330B (es) 2013-03-13 2019-04-23 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
KR102057755B1 (ko) 2013-03-13 2019-12-19 메디뮨 리미티드 피롤로벤조디아제핀 및 그의 컨쥬게이트
JP2016518382A (ja) 2013-04-26 2016-06-23 ピエール、ファーブル、メディカマン Ａｘｌ抗体薬物複合体および癌の治療のためのその使用
JP6744212B2 (ja) 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
CN110251683A (zh) 2013-06-24 2019-09-20 Abl生物公司 具有改进的稳定性的抗体-药物缀合物及其用途
KR102150616B1 (ko) 2013-09-12 2020-09-03 삼성전자주식회사 c-Met 표적 화합물-생체활성 물질 접합체 및 그 용도
GB201317981D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054992B1 (en) 2013-10-11 2019-08-14 Asana BioSciences, LLC Protein-polymer-drug conjugates
FI3122757T3 (fi) 2014-02-28 2023-10-10 Hangzhou Dac Biotech Co Ltd Varautuneita linkkereitä ja niiden konjugointikäyttötapoja
MX378944B (es) * 2014-04-18 2025-03-10 Univ New York State Res Found Anticuerpos de antígeno anti-tf humanizado.
CN106456794B (zh) 2014-05-22 2023-02-17 拜奥迪斯私人有限公司 接头药物与抗体的位点特异性缀合以及所得adc
KR102200274B1 (ko) * 2014-09-16 2021-01-08 심포젠 에이/에스 항-ｍｅｔ 항체 및 조성물
JP2018502149A (ja) * 2014-12-08 2018-01-25 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔ抗体薬物コンジュゲート
CN107613974B (zh) * 2015-03-16 2021-01-15 塞尔德克斯医疗公司 抗-met抗体及其使用方法
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EP3804765A1 (en) * 2016-05-17 2021-04-14 AbbVie Biotherapeutics Inc. Anti-cmet antibody drug conjugates and methods for their use
AU2017327658A1 (en) * 2016-09-14 2019-05-02 Merck Patent Gmbh Anti-c-MET antibodies and antibody drug conjugates thereof for efficient tumor inhibition
EP3519440A4 (en) * 2016-09-29 2020-03-25 Mitsubishi Tanabe Pharma Corporation MONOCLONAL CMET BINDERS, ACTIVE SUBSTANCE CONJUGATES AND USES THEREOF

Also Published As

Publication number Publication date
CN120586086A (zh) 2025-09-05
AU2019243764B2 (en) 2025-07-24
CA3094827A1 (en) 2019-10-03
EP3774923A4 (en) 2021-12-29
US20210163604A1 (en) 2021-06-03
IL277573B1 (en) 2025-10-01
SA520420225B1 (ar) 2025-05-15
MY208842A (en) 2025-06-02
JP2023025034A (ja) 2023-02-21
CN112119098A (zh) 2020-12-22
CN112119098B (zh) 2025-06-24
RU2020135303A (ru) 2022-04-28
SG11202009308WA (en) 2020-10-29
TW201946656A (zh) 2019-12-16
JP2024119813A (ja) 2024-09-03
CN120586086A8 (zh) 2025-10-14
TWI841555B (zh) 2024-05-11
MA52238A (fr) 2021-02-17
IL277573A (en) 2020-11-30
WO2019189453A1 (en) 2019-10-03
JP7725658B2 (ja) 2025-08-19
JP7177848B2 (ja) 2022-11-24
JP2021519319A (ja) 2021-08-10
EP3774923A1 (en) 2021-02-17
JP2025170277A (ja) 2025-11-18
JP7490736B2 (ja) 2024-05-27
BR112020019465A2 (pt) 2021-01-12
KR20200138288A (ko) 2020-12-09
PH12020551556A1 (en) 2021-06-07
AU2019243764A1 (en) 2020-11-05
US12060427B2 (en) 2024-08-13
US20250032632A1 (en) 2025-01-30

Similar Documents

Publication Publication Date Title
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
CL2018003758A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso. (divisional solicitud 201800458)
MX2023001686A (es) Anticuerpo anti-cdh6 y conjugado farmaco-anticuerpo anti-cdh6.
GEAP202214922A (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
MX2021002970A (es) Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor.
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
EA202190189A1 (ru) Сшитое производное димера пирролобензодиазепина (pbd) и его конъюгаты
DOP2023000150A (es) Conjugados de fármaco-anticuerpo activable anti-cd71 y métodos de uso de estos
PH12018500693A1 (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
GT201700102A (es) Conjugados de anticuerpo-fármaco
AR107442A1 (es) Anticuerpos contra el receptor huérfano similar al receptor tirosina quinasa 1 (anti-ror1), anticuerpos biespecíficos que se unen a ror1 y al antígeno cd3, y métodos para el tratamiento del cáncer
ECSP19044625A (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
CL2018001722A1 (es) Nuevos anticuerpos anti-mfi2 y métodos de uso (divisional solicitud 201700506)
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
EA201691650A1 (ru) Гидрофильные конъюгаты антитело-лекарственное средство
EA202091161A1 (ru) Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
MX2020010110A (es) Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.
ECSP20063690A (es) Anticuerpos
ECSP20082970A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
PE20151603A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
EA201791203A1 (ru) ЛЕКАРСТВЕННЫЙ КОНЪЮГАТ АНТИТЕЛА ПРОТИВ с-МЕТ
CL2018000131A1 (es) Inmunoconjugados de il22
MX2018000135A (es) Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2).
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.